GlassScriptPhysician profile
Mary Denise Mitchell
NPI 1215041058
$2,826.92
in general payments reported to CMS, 2019-2025
35 companies · $740 in 2025
The $740 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $527 · 2022: $490 · 2023: $453 · 2024: $616 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $852.11 | 2021-2025 | |
| Novo Nordisk INC | $373.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $244.97 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $155.51 | 2021-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $138.43 | 2021-2024 | |
| Lilly USA, LLC | $104.04 | 2024-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.77 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $88.23 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Phathom Pharmaceuticals, INC. | $60.21 | 2024-2025 | Voquezna |
| Pfizer INC. | $59.69 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.89 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $44.42 | 2021 | |
| Stryker Corporation | $44.36 | 2025 | Clottriever Bold Catheter |
| Axsome Therapeutics, INC. | $40.86 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $38.82 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $38.54 | 2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $34.05 | 2021 | |
| Abbott Laboratories | $33.80 | 2022-2023 | Freestyle Libre 2 |
| Ardelyx, INC. | $29.91 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $29.65 | 2024-2025 | Airsupra |
| Paratek Pharmaceuticals, INC. | $29.04 | 2021-2024 | Nuzyra |
| Daiichi Sankyo INC. | $24.12 | 2022 | |
| Averitas Pharma INC. | $23.60 | 2025 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $22.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.82 | 2025 | |
| Dynavax Technologies Corporation | $19.32 | 2024 | Heplisav-B |
| Lundbeck LLC | $17.14 | 2023 | Rexulti |
| Eyevance Pharmaceuticals LLC | $16.76 | 2021 | |
| Hikma Pharmaceuticals USA | $16.76 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.27 | 2021 | |
| Eisai INC. | $15.74 | 2021 | |
| Astellas Pharma US INC | $15.29 | 2021 | |
| Cashflow Solutions, LLC | $15.07 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Renalytix Ai, INC. | $14.80 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Cequr Corporation | $13.89 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.